Abstract
Purpose
To investigate whether the use of pre-orchiectomy instead of pre-chemotherapy tumor marker (TM) levels has an impact on the International Germ Cell Consensus Classification (IGCCCG) risk group assignment in patients with metastatic germ cell tumors (GCT).
Methods
Demographic and clinical information of all patients treated for primary metastatic testicular non-seminomatous GCT in our tertiary care academic center were extracted from medical charts. IGCCCG risk group assignment was correctly performed with pre-chemotherapy marker levels and additionally with pre-orchiectomy marker levels. Agreement between pre-chemotherapy and pre-orchiectomy risk group assignments was assessed using Cohen’s kappa.
Results
Our cohort consisted of 83 patients. The use of pre-orchiectomy TMs resulted in an IGCCCG risk group upstaging in 12 patients (16%, 8 patients from good to intermediate risk and 4 patients from intermediate to poor risk) and a downstaging in 1 patient (1.2%, from intermediate- to good-risk). The agreement between pre-orchiectomy and pre-chemotherapy IGCCCG risk groups resulted in a Cohen’s kappa of 0.888 (p < 0.001).
Conclusions
Using pre-orchiectomy TMs can result in incorrect IGCCCG risk group assignment, which in turn can impact on the clinical management and follow-up of patients with metastatic GCT. Thus, adherence to the IGCCCG standard using pre-chemotherapy TMs levels is recommended.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beyer J et al (2013) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24:878–888. https://doi.org/10.1093/annonc/mds579
Chovanec M, Abu Zaid M, Hanna N, El-Kouri N, Einhorn LH, Albany C (2017) Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann oncol 28:2670–2679. https://doi.org/10.1093/annonc/mdx360
Chung P, Daugaard G, Tyldesley S, Atenafu EG, Panzarella T, Kollmannsberger C, Warde P (2015) Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med 4:155–160. https://doi.org/10.1002/cam4.324
Daugaard G et al (2014) Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol 32:3817–3823. https://doi.org/10.1200/jco.2013.53.5831
DeSantis CE et al (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64:252–271. https://doi.org/10.3322/caac.21235
International-Germ-Cell-Cancer-Collaborative-Group (1997) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594–603
Kerns SL et al (2018) Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study. J Clin Oncol 36:1505–1512. https://doi.org/10.1200/JCO.2017.77.0735
Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174. https://doi.org/10.2307/2529310
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Informed consent
Informed consent was waived by the local ethic committee (STV KEK-ZH 25-2008).
Rights and permissions
About this article
Cite this article
Fankhauser, C.D., Gerke, T.A., Roth, L. et al. Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment. J Cancer Res Clin Oncol 145, 781–785 (2019). https://doi.org/10.1007/s00432-019-02844-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-019-02844-z